To Evaluate the Safety and Tolerability of Multiple Doses of GS3-007a Oral Solution in Healthy Su… (NCT05921890) | Clinical Trial Compass
CompletedPhase 1
To Evaluate the Safety and Tolerability of Multiple Doses of GS3-007a Oral Solution in Healthy Subjects.
China36 participantsStarted 2023-06-19
Plain-language summary
To evaluate the safety and tolerability of GS3-007a oral solution after multiple oral administration in Chinese healthy adult subjects.
Who can participate
Age range18 Years – 45 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy adult subjects aged 18-45 years (including boundary values), male or female;
* Body mass index: 19-26 kg/m2 (including boundary values), male weight ≥50 kg, female weight ≥45 kg;
Exclusion Criteria:
* (Screening period consultation) accumulated two or more allergies to other drugs, food and environment; Or prone to rash, urticaria and other allergic symptoms; Or are known to be allergic to growth hormone-promoting peptide drugs or excipients of this preparation;
* (screening period) have a clear history of neurological or mental disorders; Persons with incapacity or cognitive impairment;
* ALT and AST exceed the upper limit of the normal range;